The 68th Meeting on Unapproved Drugs and Off

News Highlights

On May 12, 2026, the Ministry of Health, Labour and Welfare held the 68th Meeting on Unapproved Drugs and Off-Label Drugs of High Medical Necessity online. This meeting targets unapproved drugs in Japan and drugs used for purposes other than their approved efficacy and effectiveness, focusing on those with particularly high medical necessity, to deliberate on their approval for use. The aim is to ensure prompt access opportunities for unapproved and off-label drugs.

M&A Medical Editorial Department’s Perspective

While the current “Meeting on Unapproved Drugs and Off-Label Drugs of High Medical Necessity” is directly aimed at improving drug access, from a healthcare facility management perspective, it suggests the emergence of new treatment options in specific medical fields. For instance, the potential approval of new drugs in areas where sufficient treatments have been lacking, such as for rare or intractable diseases, can directly enhance the competitiveness of clinics and hospitals specializing in those fields. In the context of M&A, such drug development trends can influence future business valuations and investment decisions in specific specialized areas. It is particularly crucial for healthcare facilities struggling with succession issues to closely monitor these drug development trends when evaluating their own specialization and future prospects, especially when considering future business continuity or sale.

Points Raised by This News

• Deliberations on unapproved and off-label drugs have the potential to strengthen responsiveness to specific medical needs.
• Trends in new drug approvals can impact the future value of specialized clinics.
• Approval of treatments for rare and intractable diseases enhances the competitive advantage of healthcare facilities in those fields.
• Drug development trends can be an evaluation factor in healthcare facilities’ business continuity and M&A strategies.

Practical Questions Arising from This News

• What specific drugs and disease areas are being considered at this meeting?
• Are there any unapproved or off-label drugs expected to be approved in the future within our clinic’s specialized field?
• What are the potential advantages and disadvantages of introducing new therapeutic drugs in terms of clinic management strategy and M&A?

If You Feel “Should I Consult?”

Are you aware of whether deliberations on unapproved and off-label drugs are progressing in your clinic’s specialized disease area, and how this might affect your future management strategy? Especially if you are considering succession or business transfer due to a lack of successors, these drug development trends can become leverage in negotiating your clinic’s business value in an M&A. Please consult with experts in medical M&A regarding specialized information gathering and integration into your future business plan.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a completely success-fee-based system as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are kept strictly confidential. Free consultation here